How to Get Farxiga (Dapagliflozin) in Colorado

Why Colorado Patients Are Seeking Farxiga

Dapagliflozin belongs to the sodium-glucose cotransporter 2 (SGLT2) inhibitor class, a group of oral medications that lower blood glucose by blocking renal glucose reabsorption. The drug has moved well beyond its original diabetes indication. In the DAPA-HF trial (N=4,744), dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo (HR 0.74; 95% CI 0.65-0.85; P<0.001), regardless of whether patients had diabetes. That result changed practice guidelines worldwide.

The DAPA-CKD trial (N=4,304) then demonstrated a 39% reduction in the composite kidney endpoint (sustained eGFR decline of ≥50%, end-stage kidney disease, or renal/cardiovascular death) with dapagliflozin versus placebo. These two large randomized trials are why Farxiga now carries three distinct FDA-approved indications: type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease with albuminuria.

Colorado has roughly 500,000 adults living with diagnosed diabetes according to CDC prevalence data, and SGLT2 inhibitors remain underused statewide. Access barriers, not lack of evidence, are the primary obstacle.

Telehealth Prescribing Is Fully Legal in Colorado

Colorado law permits licensed prescribers to evaluate patients and issue prescriptions through audio-video telehealth encounters. No in-person visit is required before a first prescription. This applies to all schedule-unscheduled medications including dapagliflozin.

A telehealth visit for Farxiga typically takes 15 to 25 minutes. The prescriber reviews your medical history, confirms the intended indication (diabetes management, heart failure, or CKD), checks baseline labs, and transmits the prescription electronically to a pharmacy of your choice. Colorado's telehealth parity law (C.R.S. § 10-16-123) requires most commercial insurers to cover telehealth visits at the same rate as in-person encounters.

Patients in rural parts of the state, from the Western Slope to the Eastern Plains, benefit most from telehealth access. Travel distances to endocrinology or cardiology clinics can exceed 100 miles in many Colorado counties. Telehealth eliminates that barrier entirely.

Who Can Prescribe Farxiga in Colorado

Three categories of clinicians hold independent prescriptive authority in Colorado and can prescribe dapagliflozin:

Physicians (MD/DO). Board-certified endocrinologists, cardiologists, nephrologists, and primary care physicians all commonly prescribe SGLT2 inhibitors. No specialist referral is required.

Nurse Practitioners (NP). Colorado granted NPs full practice authority in 2010. An NP with prescriptive authority can independently evaluate, diagnose, and prescribe Farxiga without physician oversight, per Colorado Revised Statutes § 12-255-112.

Physician Assistants (PA). PAs in Colorado prescribe under a collaborative agreement, though the supervising physician does not need to be physically present. PAs routinely manage chronic conditions including diabetes and heart failure in both primary care and specialty settings.

The practical takeaway: you are not limited to endocrinologists. Any licensed prescriber comfortable with SGLT2 inhibitor management can write the prescription.

What Labs Are Needed Before Starting Farxiga

Prescribers in Colorado follow ADA Standards of Care and the KDIGO 2024 guidelines when initiating dapagliflozin. Expect the following baseline labs:

Hemoglobin A1c. Required if the indication is type 2 diabetes. A1c confirms glycemic status and helps guide whether dapagliflozin is appropriate as monotherapy or add-on therapy.

Estimated GFR (eGFR) and serum creatinine. The current FDA label permits initiation of Farxiga for CKD at eGFR ≥25 mL/min/1.73m². For the diabetes indication, the glycemic benefit diminishes below eGFR 45. Renal function testing is non-negotiable before the first dose.

Urine albumin-to-creatinine ratio (UACR). Particularly relevant for CKD screening. The DAPA-CKD trial enrolled patients with UACR 200-5,000 mg/g, and KDIGO guidelines recommend SGLT2 inhibitors for patients with albuminuria above 30 mg/g.

Basic metabolic panel. Checks potassium, bicarbonate, and glucose. SGLT2 inhibitors carry a small risk of euglycemic diabetic ketoacidosis (eDKA), and baseline metabolic status helps stratify that risk.

Complete blood count. Some prescribers request a CBC to rule out anemia or infection before starting therapy.

Most of these labs can be ordered through a telehealth visit and completed at any Quest, Labcorp, or hospital-affiliated draw station across Colorado. Results typically return within 24 to 48 hours.

Colorado Medicaid Coverage: Gaps and Workarounds

Colorado Medicaid (Health First Colorado) does not cover Farxiga for type 2 diabetes as a standalone indication. This is a significant access gap. The preferred SGLT2 inhibitor on the Colorado Medicaid formulary has historically been empagliflozin (Jardiance), though formulary placement shifts annually.

For heart failure or CKD indications, coverage pathways may differ. Medicaid managed care organizations (MCOs) in Colorado, including Rocky Mountain Health Plans, Colorado Access, and Denver Health Medical Plan, each maintain separate formularies. Some MCOs have added dapagliflozin for heart failure following the DAPA-HF data. The 2022 AHA/ACC/HFSA heart failure guideline gives SGLT2 inhibitors a Class I recommendation for HFrEF, which strengthens the medical necessity argument on appeal.

If your MCO denies initial coverage, you have three options:

1. Step therapy exception. If you have tried and failed empagliflozin or another formulary-preferred agent, submit documentation of intolerance or inadequate response.
2. Prior authorization appeal. Provide the prescriber's clinical rationale, relevant trial data (DAPA-HF, DAPA-CKD), and current guideline recommendations.
3. Manufacturer patient assistance. AstraZeneca's Farxiga patient assistance program provides the drug at no cost to qualifying uninsured or underinsured patients with household incomes below 300% of the federal poverty level.

Commercial Insurance and Prior Authorization in Colorado

Most commercial plans in Colorado, including those offered through Anthem, Cigna, United Healthcare, and Kaiser Permanente of Colorado, cover Farxiga on a preferred or non-preferred branded tier. Prior authorization is the norm, not the exception.

The typical prior authorization packet includes:

• Diagnosis code. ICD-10 codes E11.x (type 2 diabetes), I50.x (heart failure), or N18.x (chronic kidney disease).
• Lab results. A1c, eGFR, UACR, and metabolic panel within the past 90 days.
• Treatment history. Documentation of metformin use (for diabetes) or ACE/ARB use (for CKD/HF) as first-line therapy.
• Clinical rationale. A prescriber letter citing guideline recommendations and patient-specific factors.

Processing time varies. Expect 3 to 7 business days for a standard determination. Colorado insurance law requires urgent prior authorization decisions within 24 hours when the prescriber attests that delay would seriously jeopardize the patient's health.

AstraZeneca offers a commercial copay savings card that reduces out-of-pocket cost to as low as $0 per month for eligible commercially insured patients, with a maximum annual benefit (typically $1,800 to $2,400 per year). This card does not apply to government insurance programs including Medicaid, Medicare, or Tricare.

Pharmacy Access and 503A Compounding in Colorado

Farxiga is available at all major retail pharmacy chains operating in Colorado: Walgreens, CVS, King Soopers (Kroger), Safeway, Walmart, and Costco. Independent pharmacies can also order dapagliflozin through standard wholesale distributors.

The cash price for a 30-day supply of brand-name Farxiga 10 mg typically ranges from $550 to $620 without insurance. GoodRx and similar discount platforms may reduce this to $480 to $540 at select Colorado pharmacies.

503A compounding pharmacies. Colorado licenses 503A compounding pharmacies through the Colorado State Board of Pharmacy. A 503A pharmacy can compound dapagliflozin preparations based on a valid patient-specific prescription. This pathway is sometimes used when patients need non-standard dosing, have tablet-swallowing difficulties, or when cost considerations favor a compounded preparation.

Key requirements for 503A dispensing in Colorado:

• A valid prescription from a Colorado-licensed or telehealth-authorized prescriber
• The compounded product must be for an individually identified patient
• The pharmacy must hold a current Colorado compounding license
• The preparation cannot be a copy of a commercially available product in the same strength and dosage form, unless the prescriber documents a clinical reason for the compounded version

503A pharmacies in Colorado can ship compounded medications within the state. Interstate shipping from a 503A pharmacy is permitted only if the receiving state also allows it.

Step-by-Step: Getting Your Farxiga Prescription in Colorado

Step 1. Schedule a visit. Book an appointment with a licensed prescriber (MD, DO, NP, or PA) in Colorado. Telehealth is acceptable for the initial evaluation.

Step 2. Complete baseline labs. Have A1c, eGFR, UACR, and a basic metabolic panel drawn at any Colorado lab facility. Many telehealth platforms issue lab orders that can be completed at Quest or Labcorp locations throughout the Front Range, mountain communities, and the Western Slope.

Step 3. Clinical evaluation. Your prescriber reviews labs, medical history, current medications, and determines whether dapagliflozin is appropriate. The prescriber selects the indication (T2D, HF, or CKD) and dosing (typically 10 mg once daily; 5 mg for some patients).

Step 4. Prescription transmission. The prescriber sends the electronic prescription to your preferred pharmacy.

Step 5. Prior authorization (if required). Your prescriber's office submits the PA packet to your insurer. Monitor the timeline: 3-7 business days standard, 24 hours urgent.

Step 6. Fill and start therapy. Pick up your medication or arrange home delivery. Most Colorado pharmacies offer mail-order or delivery options.

Step 7. Follow-up labs. Expect repeat eGFR and metabolic panel at 1 to 3 months after initiation, then every 6 to 12 months per KDIGO monitoring recommendations.

Transferring an Existing Farxiga Prescription to Colorado

If you are moving to Colorado or visiting for an extended period, you can transfer an active Farxiga prescription from another state. Colorado Board of Pharmacy rules allow prescription transfers between licensed pharmacies. The process:

1. Contact your new Colorado pharmacy with your current pharmacy's name and phone number.
2. The receiving pharmacist calls the originating pharmacy to verify and transfer the prescription record.
3. Remaining refills transfer to the new location.

For telehealth patients, your out-of-state prescriber must hold a Colorado medical license or your prescription must be reissued by a Colorado-licensed provider. Colorado does not honor prescriptions written by providers who lack Colorado licensure, with limited exceptions for bordering-state emergency care.

Safety Monitoring and Ongoing Care

SGLT2 inhibitors are generally well tolerated, but Colorado prescribers monitor for specific adverse effects. Genital mycotic infections (yeast infections) occur in approximately 6-8% of women and 3-5% of men on dapagliflozin, per FDA prescribing information. Volume depletion risk increases in patients over 65 or those taking loop diuretics. The rare but serious risk of euglycemic DKA requires patient education about symptoms (nausea, vomiting, abdominal pain, fatigue) and clear instructions to hold dapagliflozin during acute illness, surgery, or prolonged fasting.

The 2024 ADA Standards of Care recommend SGLT2 inhibitors as first-line add-on therapy for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, independent of A1c. This recommendation is based on the cardiovascular and renal outcome benefits demonstrated in DAPA-HF and DAPA-CKD, not merely glycemic control.

Colorado altitude may increase dehydration risk, particularly for patients in mountain communities above 7,000 feet. Prescribers in Summit, Eagle, Pitkin, and similar high-altitude counties often emphasize hydration counseling when initiating SGLT2 inhibitors. Dapagliflozin 10 mg once daily with adequate fluid intake remains the standard approach at any elevation.